306 related articles for article (PubMed ID: 25488117)
1. Fc fusion as a platform technology: potential for modulating immunogenicity.
Levin D; Golding B; Strome SE; Sauna ZE
Trends Biotechnol; 2015 Jan; 33(1):27-34. PubMed ID: 25488117
[TBL] [Abstract][Full Text] [Related]
2. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
Huang C
Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
[TBL] [Abstract][Full Text] [Related]
3. Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.
Soleimanpour S; Hassannia T; Motiee M; Amini AA; Rezaee SA
Crit Rev Biotechnol; 2017 May; 37(3):371-392. PubMed ID: 27049690
[TBL] [Abstract][Full Text] [Related]
4. Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics.
Ng CL; Lim TS; Choong YS
Mol Biotechnol; 2024 Apr; 66(4):568-581. PubMed ID: 37742298
[TBL] [Abstract][Full Text] [Related]
5. Harnessing Fc receptor biology in the design of therapeutic antibodies.
Sondermann P; Szymkowski DE
Curr Opin Immunol; 2016 Jun; 40():78-87. PubMed ID: 27038127
[TBL] [Abstract][Full Text] [Related]
6. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
7. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
8. B Cell-Based Seamless Engineering of Antibody Fc Domains.
Hashimoto K; Kurosawa K; Murayama A; Seo H; Ohta K
PLoS One; 2016; 11(12):e0167232. PubMed ID: 27907066
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Fc-mediated effector functions of monoclonal antibodies.
Strohl WR
Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
[TBL] [Abstract][Full Text] [Related]
11. Advances in the assessment and control of the effector functions of therapeutic antibodies.
Jiang XR; Song A; Bergelson S; Arroll T; Parekh B; May K; Chung S; Strouse R; Mire-Sluis A; Schenerman M
Nat Rev Drug Discov; 2011 Feb; 10(2):101-11. PubMed ID: 21283105
[TBL] [Abstract][Full Text] [Related]
12. Optimizing therapeutic antibody function: progress with Fc domain engineering.
Kaneko E; Niwa R
BioDrugs; 2011 Feb; 25(1):1-11. PubMed ID: 21033767
[TBL] [Abstract][Full Text] [Related]
13. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
14. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
15. A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies.
Furlong MT; Ouyang Z; Wu S; Tamura J; Olah T; Tymiak A; Jemal M
Biomed Chromatogr; 2012 Aug; 26(8):1024-32. PubMed ID: 22623136
[TBL] [Abstract][Full Text] [Related]
16. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.
Zheng XX; Steele AW; Hancock WW; Kawamoto K; Li XC; Nickerson PW; Li Y; Tian Y; Strom TB
J Immunol; 1999 Oct; 163(7):4041-8. PubMed ID: 10491008
[TBL] [Abstract][Full Text] [Related]
17. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
18. Next-generation Fc chimeric proteins: avoiding immune-system interactions.
Junghans RP
Trends Biotechnol; 1997 May; 15(5):155. PubMed ID: 9161048
[No Abstract] [Full Text] [Related]
19. Introduction to current and future protein therapeutics: a protein engineering perspective.
Carter PJ
Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic antibodies and related products: choosing the right structure for success].
Beck A; Wagner-Rousset E; Wurch T; Corvaia N
Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
